Nedaplatin: A Radiosensitizing Agent for Patients with Cervical Cancer
Open Access
- 21 September 2010
- journal article
- review article
- Published by Hindawi Limited in Chemotherapy Research and Practice
- Vol. 2011, 1-10
- https://doi.org/10.1155/2011/963159
Abstract
Despite the recent advances in the management of cervical cancer using cisplatin-based concurrent chemoradiotherapy, substantial treatment failure still occurs, especially in advanced-stage patients and early-stage cervical cancer patients with high-risk prognostic factors. Therefore, efforts to further improve the survival and quality of life of these patients are necessary. Nedaplatin (cis-diammine-glycoplatinum), a derivative of cisplatin, was developed with the aim of producing a treatment with a similar effectiveness to cisplatin but decreased renal and gastrointestinal toxicities. Based on the promising results of preclinical studies, the clinical efficacy of nedaplatin as a radiosensitizing agent was evaluated in patients with cervical cancer. Retrospective analysis of nedaplatin-based concurrent chemoradiotherapy (CCRT) against cervical cancer suggested that nedaplatin-based CCRT can be considered as an alternative to cisplatin-based CCRT in both early-stage and advanced-stage cervical cancer patients. However, due to the lack of a randomized controlled study, nedaplatin-based CCRT has not been convincingly proven to be clinically effective in patients with cervical cancer. Further investigations in randomized controlled trials are therefore needed.Keywords
This publication has 45 references indexed in Scilit:
- Reducing Uncertainties About the Effects of Chemoradiotherapy for Cervical Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 18 Randomized TrialsJournal of Clinical Oncology, 2008
- Efficacy and toxicity of concomitant cisplatin with external beam pelvic radiotherapy and two high-dose-rate brachytherapy insertions for the treatment of locally advanced cervical cancerGynecologic Oncology, 2007
- Feasibility of concurrent cisplatin use during primary and adjuvant chemoradiation therapy: a phase I study in Japanese patients with cancer of the uterine cervixInternational Journal of Clinical Oncology, 2006
- Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II studyGynecologic Oncology, 2005
- Carcinoma of the cervix uteriInternational Journal of Gynecology & Obstetrics, 2003
- ChemoradiotherapyDrugs, 2000
- In VitroPhase II Comparison of the Cytotoxicity of a Novel Platinum Analog, Nedaplatin (254-S), with That of Cisplatin and Carboplatin against Fresh, Human Cervical CancersGynecologic Oncology, 1998
- Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancerThe Lancet, 1997
- Prognostic significance of ureteral obstruction in primary cervical cancerInternational Journal of Gynecology & Obstetrics, 1994
- Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: A Gynecologic Oncology Group studyGynecologic Oncology, 1990